Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-05

AUTHORS

Shinzaburo Noguchi, Matthew J. Ellis, John F. R. Robertson, Jackie Thirlwell, Mehdi Fazal, Zhimin Shao

ABSTRACT

BACKGROUND: The international, phase III FALCON study (NCT01602380) in postmenopausal patients with hormone receptor-positive, locally advanced/metastatic breast cancer (LA/MBC) who had not received prior endocrine therapy, demonstrated statistically significant improvement in progression-free survival (PFS) for patients who received fulvestrant 500 mg vs anastrozole 1 mg. This subgroup analysis evaluated PFS in Asian (randomized in China, Japan, or Taiwan) and non-Asian patients from the FALCON study. METHODS: Eligible patients (estrogen receptor- and/or progesterone receptor-positive LA/MBC; World Health Organization performance status 0-2; ≥ 1 measurable/non-measurable lesion[s]) were randomized. PFS was assessed via Response Evaluation Criteria in Solid Tumours version 1.1, surgery/radiotherapy for disease worsening, or death (any cause). Secondary endpoints included: objective response rate, clinical benefit rate, duration of response, and duration of clinical benefit. Consistency of effect across subgroups was assessed via hazard ratios and 95% confidence intervals (CIs) using a log-rank test. Adverse events (AEs) were evaluated. RESULTS: Of the 462 randomized patients, the Asian and non-Asian subgroups comprised 67 and 395 patients, respectively. In the Asian subgroup, median PFS was 16.6 and 15.9 months with fulvestrant and anastrozole, respectively (hazard ratio 0.81; 95% CI 0.44-1.50). In the non-Asian subgroup, median PFS was 16.5 and 13.8 months, respectively (hazard ratio 0.79; 95% CI 0.62-1.01). Secondary outcomes were numerically improved with fulvestrant vs anastrozole in both subgroups. AE profiles were generally consistent between Asian and non-Asian subgroups. CONCLUSIONS: Results of this subgroup analysis suggest that treatment effects in the Asian patient subgroup are broadly consistent with the non-Asian population. More... »

PAGES

356-364

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12282-018-0838-8

DOI

http://dx.doi.org/10.1007/s12282-018-0838-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101057009

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29450827


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "China", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estradiol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Response Evaluation Criteria in Solid Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taiwan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Osaka University", 
          "id": "https://www.grid.ac/institutes/grid.136593.b", 
          "name": [
            "Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noguchi", 
        "givenName": "Shinzaburo", 
        "id": "sg:person.01030141447.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030141447.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor College of Medicine", 
          "id": "https://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Lester and Sue Smith Breast Center, Baylor Clinic, Baylor College of Medicine, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ellis", 
        "givenName": "Matthew J.", 
        "id": "sg:person.012333564657.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012333564657.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Nottingham", 
          "id": "https://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "John F. R.", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thirlwell", 
        "givenName": "Jackie", 
        "id": "sg:person.011231414417.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011231414417.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fazal", 
        "givenName": "Mehdi", 
        "id": "sg:person.07716313051.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07716313051.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fudan University Shanghai Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Fudan University Shanghai Cancer Center, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shao", 
        "givenName": "Zhimin", 
        "id": "sg:person.015216426717.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015216426717.30"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6604721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001882911", 
          "https://doi.org/10.1038/sj.bjc.6604721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.8415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004144759"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.11468", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007461265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.67.1487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010471013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)32389-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014303949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.1136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017723747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12282-013-0444-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018435401", 
          "https://doi.org/10.1007/s12282-013-0444-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.61.5831", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021203815"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-1022-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028916628", 
          "https://doi.org/10.1007/s10549-010-1022-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-1022-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028916628", 
          "https://doi.org/10.1007/s10549-010-1022-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.thorsurg.2014.12.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032347522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-012-2192-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032719812", 
          "https://doi.org/10.1007/s10549-012-2192-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq249", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038899124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.10254", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039600725"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0993", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043446019"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1483-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045449451", 
          "https://doi.org/10.1007/s00280-010-1483-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1483-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045449451", 
          "https://doi.org/10.1007/s00280-010-1483-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2016.10.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046767167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.058", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078473204", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092559985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092559985"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-05", 
    "datePublishedReg": "2018-05-01", 
    "description": "BACKGROUND: The international, phase III FALCON study (NCT01602380) in postmenopausal patients with hormone receptor-positive, locally advanced/metastatic breast cancer (LA/MBC) who had not received prior endocrine therapy, demonstrated statistically significant improvement in progression-free survival (PFS) for patients who received fulvestrant 500\u00a0mg vs anastrozole 1\u00a0mg. This subgroup analysis evaluated PFS in Asian (randomized in China, Japan, or Taiwan) and non-Asian patients from the FALCON study.\nMETHODS: Eligible patients (estrogen receptor- and/or progesterone receptor-positive LA/MBC; World Health Organization performance status 0-2; \u2265\u00a01 measurable/non-measurable lesion[s]) were randomized. PFS was assessed via Response Evaluation Criteria in Solid Tumours version 1.1, surgery/radiotherapy for disease worsening, or death (any cause). Secondary endpoints included: objective response rate, clinical benefit rate, duration of response, and duration of clinical benefit. Consistency of effect across subgroups was assessed via hazard ratios and 95% confidence intervals (CIs) using a log-rank test. Adverse events (AEs) were evaluated.\nRESULTS: Of the 462 randomized patients, the Asian and non-Asian subgroups comprised 67 and 395 patients, respectively. In the Asian subgroup, median PFS was 16.6 and 15.9\u00a0months with fulvestrant and anastrozole, respectively (hazard ratio 0.81; 95% CI 0.44-1.50). In the non-Asian subgroup, median PFS was 16.5 and 13.8\u00a0months, respectively (hazard ratio 0.79; 95% CI 0.62-1.01). Secondary outcomes were numerically improved with fulvestrant vs anastrozole in both subgroups. AE profiles were generally consistent between Asian and non-Asian subgroups.\nCONCLUSIONS: Results of this subgroup analysis suggest that treatment effects in the Asian patient subgroup are broadly consistent with the non-Asian population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12282-018-0838-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "name": "Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)", 
    "pagination": "356-364", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f033250348d98b40ac188687790b464f2721a104516767fefce24b55caac55c7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29450827"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100888201"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12282-018-0838-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101057009"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12282-018-0838-8", 
      "https://app.dimensions.ai/details/publication/pub.1101057009"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000519.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s12282-018-0838-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-018-0838-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-018-0838-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-018-0838-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-018-0838-8'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      21 PREDICATES      71 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12282-018-0838-8 schema:about N0fefa48294554da18165b4201e13a960
2 N1bc6e73c9a854d50873ba16876562f72
3 N20f1cd90a5c84abb98bdc6166a411654
4 N3459cb1268cb410f9e284dc28430316f
5 N53220c0db62745f6a9dfc48afe3ae915
6 N543ff91e80614936bcf7f69c559ab8bb
7 N754f8b109c654552ba292da3b50b2f05
8 N95d4a55c29a6497a90e4e993547210b9
9 N99e5a790471c4991a07a6470d4c5b7d9
10 N9d24ffa142874f859fff45e6132759d3
11 Na32a5f597a7a47aaa8b805b88231883e
12 Na62707a6cf704a23be5b8cd75ebf385e
13 Nad655763ca854bc196481c70e4eda6db
14 Nb803ce14f9064182855193bf3db61b00
15 Nba9ca3a1fd774c76ae4e2e43f0909abc
16 Nc3d65782da2b43898f772196e4189c64
17 Ncb7ca5e76e0448debf09209349b012f9
18 Ne00daa2c62d74b208741e5e131989998
19 Ne5730a9de371481cae8c5da989783110
20 Ne80b3810311a44f09271504b5426c737
21 Nf3c18f044e86481683460c060203eefe
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N4804114b12b64dc5b292dfc02a8be309
25 schema:citation sg:pub.10.1007/s00280-010-1483-x
26 sg:pub.10.1007/s10549-010-1022-9
27 sg:pub.10.1007/s10549-012-2192-4
28 sg:pub.10.1007/s12282-013-0444-8
29 sg:pub.10.1038/sj.bjc.6604721
30 https://app.dimensions.ai/details/publication/pub.1078473204
31 https://doi.org/10.1002/cncr.11468
32 https://doi.org/10.1016/j.breast.2016.10.001
33 https://doi.org/10.1016/j.thorsurg.2014.12.003
34 https://doi.org/10.1016/s0140-6736(16)32389-3
35 https://doi.org/10.1093/annonc/mdq249
36 https://doi.org/10.1093/annonc/mdx447
37 https://doi.org/10.1093/jnci/92.3.205
38 https://doi.org/10.1158/1078-0432.ccr-08-0993
39 https://doi.org/10.1200/jco.2002.10.057
40 https://doi.org/10.1200/jco.2002.10.058
41 https://doi.org/10.1200/jco.2008.21.1136
42 https://doi.org/10.1200/jco.2010.28.8415
43 https://doi.org/10.1200/jco.2015.61.5831
44 https://doi.org/10.1200/jco.2016.67.1487
45 https://doi.org/10.18632/oncotarget.10254
46 schema:datePublished 2018-05
47 schema:datePublishedReg 2018-05-01
48 schema:description BACKGROUND: The international, phase III FALCON study (NCT01602380) in postmenopausal patients with hormone receptor-positive, locally advanced/metastatic breast cancer (LA/MBC) who had not received prior endocrine therapy, demonstrated statistically significant improvement in progression-free survival (PFS) for patients who received fulvestrant 500 mg vs anastrozole 1 mg. This subgroup analysis evaluated PFS in Asian (randomized in China, Japan, or Taiwan) and non-Asian patients from the FALCON study. METHODS: Eligible patients (estrogen receptor- and/or progesterone receptor-positive LA/MBC; World Health Organization performance status 0-2; ≥ 1 measurable/non-measurable lesion[s]) were randomized. PFS was assessed via Response Evaluation Criteria in Solid Tumours version 1.1, surgery/radiotherapy for disease worsening, or death (any cause). Secondary endpoints included: objective response rate, clinical benefit rate, duration of response, and duration of clinical benefit. Consistency of effect across subgroups was assessed via hazard ratios and 95% confidence intervals (CIs) using a log-rank test. Adverse events (AEs) were evaluated. RESULTS: Of the 462 randomized patients, the Asian and non-Asian subgroups comprised 67 and 395 patients, respectively. In the Asian subgroup, median PFS was 16.6 and 15.9 months with fulvestrant and anastrozole, respectively (hazard ratio 0.81; 95% CI 0.44-1.50). In the non-Asian subgroup, median PFS was 16.5 and 13.8 months, respectively (hazard ratio 0.79; 95% CI 0.62-1.01). Secondary outcomes were numerically improved with fulvestrant vs anastrozole in both subgroups. AE profiles were generally consistent between Asian and non-Asian subgroups. CONCLUSIONS: Results of this subgroup analysis suggest that treatment effects in the Asian patient subgroup are broadly consistent with the non-Asian population.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree false
52 schema:isPartOf N790cdf93db0a458ab161ccfd603ef9a1
53 Nf282305cc30744fba5965220706cae6d
54 sg:journal.1021080
55 schema:name Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
56 schema:pagination 356-364
57 schema:productId N0bf11db6823245c9b22630cdf789a577
58 N8c3e3cf587a04513a64813015fd1e047
59 N92f01c419857474e8047716ab09dfa5c
60 Nbd07f584b10e4b6cbceb009a712a741b
61 Nf4b7d53f206c4810ae40b4a3773f7520
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101057009
63 https://doi.org/10.1007/s12282-018-0838-8
64 schema:sdDatePublished 2019-04-10T13:19
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher Ne8174f0d57724e1481d23101473a7743
67 schema:url http://link.springer.com/10.1007/s12282-018-0838-8
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N09ba3998e8324dd69f65d2808fe254fd rdf:first sg:person.011231414417.36
72 rdf:rest N5cee036cca364ccc904f4eb822f25614
73 N0bf11db6823245c9b22630cdf789a577 schema:name dimensions_id
74 schema:value pub.1101057009
75 rdf:type schema:PropertyValue
76 N0fefa48294554da18165b4201e13a960 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Nitriles
78 rdf:type schema:DefinedTerm
79 N1bc6e73c9a854d50873ba16876562f72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Receptors, Estrogen
81 rdf:type schema:DefinedTerm
82 N20f1cd90a5c84abb98bdc6166a411654 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Female
84 rdf:type schema:DefinedTerm
85 N3459cb1268cb410f9e284dc28430316f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Taiwan
87 rdf:type schema:DefinedTerm
88 N4804114b12b64dc5b292dfc02a8be309 rdf:first sg:person.01030141447.93
89 rdf:rest N7edc1522b12847ee80e8d92deefb47e9
90 N53220c0db62745f6a9dfc48afe3ae915 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Estradiol
92 rdf:type schema:DefinedTerm
93 N543ff91e80614936bcf7f69c559ab8bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name China
95 rdf:type schema:DefinedTerm
96 N55b98f60520143c19b5ee3a865754d63 rdf:first sg:person.07764637207.20
97 rdf:rest N09ba3998e8324dd69f65d2808fe254fd
98 N5cee036cca364ccc904f4eb822f25614 rdf:first sg:person.07716313051.54
99 rdf:rest Na14aafd284774c178590366e4c33ce72
100 N754f8b109c654552ba292da3b50b2f05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Postmenopause
102 rdf:type schema:DefinedTerm
103 N790cdf93db0a458ab161ccfd603ef9a1 schema:issueNumber 3
104 rdf:type schema:PublicationIssue
105 N7edc1522b12847ee80e8d92deefb47e9 rdf:first sg:person.012333564657.16
106 rdf:rest N55b98f60520143c19b5ee3a865754d63
107 N8c3e3cf587a04513a64813015fd1e047 schema:name readcube_id
108 schema:value f033250348d98b40ac188687790b464f2721a104516767fefce24b55caac55c7
109 rdf:type schema:PropertyValue
110 N92f01c419857474e8047716ab09dfa5c schema:name nlm_unique_id
111 schema:value 100888201
112 rdf:type schema:PropertyValue
113 N95d4a55c29a6497a90e4e993547210b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Aged, 80 and over
115 rdf:type schema:DefinedTerm
116 N99e5a790471c4991a07a6470d4c5b7d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Breast
118 rdf:type schema:DefinedTerm
119 N9d24ffa142874f859fff45e6132759d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Receptor, ErbB-2
121 rdf:type schema:DefinedTerm
122 Na14aafd284774c178590366e4c33ce72 rdf:first sg:person.015216426717.30
123 rdf:rest rdf:nil
124 Na32a5f597a7a47aaa8b805b88231883e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Humans
126 rdf:type schema:DefinedTerm
127 Na62707a6cf704a23be5b8cd75ebf385e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Response Evaluation Criteria in Solid Tumors
129 rdf:type schema:DefinedTerm
130 Nad655763ca854bc196481c70e4eda6db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Japan
132 rdf:type schema:DefinedTerm
133 Nb803ce14f9064182855193bf3db61b00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Aged
135 rdf:type schema:DefinedTerm
136 Nba9ca3a1fd774c76ae4e2e43f0909abc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Disease-Free Survival
138 rdf:type schema:DefinedTerm
139 Nbd07f584b10e4b6cbceb009a712a741b schema:name pubmed_id
140 schema:value 29450827
141 rdf:type schema:PropertyValue
142 Nc3d65782da2b43898f772196e4189c64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Middle Aged
144 rdf:type schema:DefinedTerm
145 Ncb7ca5e76e0448debf09209349b012f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Antineoplastic Agents, Hormonal
147 rdf:type schema:DefinedTerm
148 Ne00daa2c62d74b208741e5e131989998 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Receptors, Progesterone
150 rdf:type schema:DefinedTerm
151 Ne5730a9de371481cae8c5da989783110 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Adult
153 rdf:type schema:DefinedTerm
154 Ne80b3810311a44f09271504b5426c737 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Breast Neoplasms
156 rdf:type schema:DefinedTerm
157 Ne8174f0d57724e1481d23101473a7743 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 Nf282305cc30744fba5965220706cae6d schema:volumeNumber 25
160 rdf:type schema:PublicationVolume
161 Nf3c18f044e86481683460c060203eefe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Triazoles
163 rdf:type schema:DefinedTerm
164 Nf4b7d53f206c4810ae40b4a3773f7520 schema:name doi
165 schema:value 10.1007/s12282-018-0838-8
166 rdf:type schema:PropertyValue
167 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
168 schema:name Medical and Health Sciences
169 rdf:type schema:DefinedTerm
170 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
171 schema:name Clinical Sciences
172 rdf:type schema:DefinedTerm
173 sg:journal.1021080 schema:issn 1340-6868
174 1880-4233
175 schema:name Breast Cancer
176 rdf:type schema:Periodical
177 sg:person.01030141447.93 schema:affiliation https://www.grid.ac/institutes/grid.136593.b
178 schema:familyName Noguchi
179 schema:givenName Shinzaburo
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030141447.93
181 rdf:type schema:Person
182 sg:person.011231414417.36 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
183 schema:familyName Thirlwell
184 schema:givenName Jackie
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011231414417.36
186 rdf:type schema:Person
187 sg:person.012333564657.16 schema:affiliation https://www.grid.ac/institutes/grid.39382.33
188 schema:familyName Ellis
189 schema:givenName Matthew J.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012333564657.16
191 rdf:type schema:Person
192 sg:person.015216426717.30 schema:affiliation https://www.grid.ac/institutes/grid.452404.3
193 schema:familyName Shao
194 schema:givenName Zhimin
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015216426717.30
196 rdf:type schema:Person
197 sg:person.07716313051.54 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
198 schema:familyName Fazal
199 schema:givenName Mehdi
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07716313051.54
201 rdf:type schema:Person
202 sg:person.07764637207.20 schema:affiliation https://www.grid.ac/institutes/grid.4563.4
203 schema:familyName Robertson
204 schema:givenName John F. R.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
206 rdf:type schema:Person
207 sg:pub.10.1007/s00280-010-1483-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045449451
208 https://doi.org/10.1007/s00280-010-1483-x
209 rdf:type schema:CreativeWork
210 sg:pub.10.1007/s10549-010-1022-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028916628
211 https://doi.org/10.1007/s10549-010-1022-9
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/s10549-012-2192-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032719812
214 https://doi.org/10.1007/s10549-012-2192-4
215 rdf:type schema:CreativeWork
216 sg:pub.10.1007/s12282-013-0444-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018435401
217 https://doi.org/10.1007/s12282-013-0444-8
218 rdf:type schema:CreativeWork
219 sg:pub.10.1038/sj.bjc.6604721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001882911
220 https://doi.org/10.1038/sj.bjc.6604721
221 rdf:type schema:CreativeWork
222 https://app.dimensions.ai/details/publication/pub.1078473204 schema:CreativeWork
223 https://doi.org/10.1002/cncr.11468 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007461265
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/j.breast.2016.10.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046767167
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1016/j.thorsurg.2014.12.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032347522
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1016/s0140-6736(16)32389-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014303949
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/annonc/mdq249 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038899124
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1093/annonc/mdx447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092559985
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1158/1078-0432.ccr-08-0993 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043446019
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1200/jco.2002.10.057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203147
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2002.10.058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203148
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.2008.21.1136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017723747
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1200/jco.2010.28.8415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004144759
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1200/jco.2015.61.5831 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021203815
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1200/jco.2016.67.1487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010471013
250 rdf:type schema:CreativeWork
251 https://doi.org/10.18632/oncotarget.10254 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039600725
252 rdf:type schema:CreativeWork
253 https://www.grid.ac/institutes/grid.136593.b schema:alternateName Osaka University
254 schema:name Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.39382.33 schema:alternateName Baylor College of Medicine
257 schema:name Lester and Sue Smith Breast Center, Baylor Clinic, Baylor College of Medicine, Houston, TX, USA
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
260 schema:name AstraZeneca, Cambridge, UK
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
263 schema:name AstraZeneca, Gaithersburg, MD, USA
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.452404.3 schema:alternateName Fudan University Shanghai Cancer Center
266 schema:name Fudan University Shanghai Cancer Center, Shanghai, China
267 rdf:type schema:Organization
268 https://www.grid.ac/institutes/grid.4563.4 schema:alternateName University of Nottingham
269 schema:name Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, UK
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...